In vitro skin absorption and drug release - A comparison of six commercial prednicarbate preparations for topical use

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 68, Issue 2, 2008, Pages 380-389

  Lombardi Borgia, S ^a   Schlupp, P ^a,b   Mehnert, W ^a   Schafer Korting M ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Drug release; Prednicarbate; Reconstructed human epidermis; Skin absorption; Skin metabolism; Topical dermatics

Indexed keywords

PREDNICARBATE; PREDNITOP; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CREAM; DRUG ABSORPTION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; DRUG TOLERABILITY; DRUG UPTAKE; ENZYME DEGRADATION; OINTMENT; SKIN ABSORPTION; SKIN CULTURE;

ADMINISTRATION, TOPICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MODELS, BIOLOGICAL; PREDNISOLONE; SKIN ABSORPTION;

EID: 37849044525     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.05.003     Document Type: Article

References (53)

1. OECD, Skin absorption: in vitro Method. Guideline 428, 2004.
2. OECD, Guidance Document for the Conduct of Skin Absorption Studies. Series on Testing Assessment 28, 2003.
3. van de Sandt J.J., van Burgsteden J.A., Cage S., Carmichael P.L., Dick I., Kenyon S., Korinth G., Larese F., Limasset J.C., Maas W.J., Montomoli L., Nielsen J.B., Payan J.P., Robinson E., Sartorelli P., Schaller K.H., Wilkinson S.C., and Williams F.M. In vitro predictions of skin absorption of caffeine, testosterone, and benzoic acid: a multi-centre comparison study. Regul. Toxicol. Pharmacol. 39 (2004) 271-281
4. Netzlaff F., Lehr C.M., Wertz P.W., and Schäfer U.F. The human epidermis models EpiSkin, SkinEthic and EpiDerm: an evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. Eur. J. Pharm Biopharm. 60 (2005) 167-178
5. Schäfer-Korting M., Bock U., Gamer A., Haberland A., Haltner-Ukomadu E., Kaca M., Kamp H., Kietzmann M., Korting H.C., Krächter H.U., Lehr C.M., Liebsch M., Mehling A., Netzlaff F., Niedorf F., Rübbelke M.K., Schäfer U., Schmidt E., Schreiber S., Schröder K.R., Spielmann H., and Vuia A. Reconstructed human epidermis for skin absorption testing: results of the German prevalidation study. Altern. Lab. Anim. 34 (2006) 283-294
6. Schreiber S., Mahmoud A., Vuia A., Rübbelke M.K., Schmidt E., Schaller M., Kandarova H., Haberland A., Schäfer U.F., Bock U., Korting H.C., Liebsch M., and Schäfer-Korting M. Reconstructed epidermis versus human and animal skin in skin absorption studies. Toxicol. In Vitro 19 (2005) 813-822
7. Gysler A., Kleuser B., Sippl W., Lange K., Korting H.C., Holtje H.D., and Schäfer-Korting M. Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm. Res. 16 (1999) 1386-1391
8. Santos Maia C., Mehnert W., Schaller M., Korting H.C., Gysler A., Haberland A., and Schäfer-Korting M. Drug targeting by solid lipid nanoparticles for dermal use. J. Drug. Target. 10 (2002) 489-495
9. Mahmoud A., Haberland A., Dürrfeld M., Heydeck D., Wagner S., and Schäfer-Korting M. Cutaneous estradiol permeation, penetration and metabolism in pig and man. Skin Pharmacol. Physiol. 18 (2005) 27-35
10. Marty J.P. New trends in transdermal technologies: development of the skin patch, Menorest. Int. J. Gynaecol. Obstet. 52 Suppl. 1 (1996) S17-S20
11. Wagner H., Kostka K.H., Adelhardt W., and Schäfer U.F. Effects of various vehicles on the penetration of flufenamic acid into human skin. Eur. J. Pharm. Biopharm. 58 (2004) 121-129
12. Wagner H., Kostka K.H., Lehr C.M., and Schäfer U.F. Interrelation of permeation and penetration parameters obtained from in vitro experiments with human skin and skin equivalents. J. Control. Release 75 (2001) 283-295
13. Tas C., Ozkan Y., Savaser A., and Baykara T. In vitro and ex vivo permeation studies of chlorpheniramine maleate gels prepared by carbomer derivatives. Drug Dev. Ind. Pharm. 30 (2004) 637-647
14. Dreher F., Fouchard F., Patouillet C., Andrian M., Simonnet J.T., and Benech-Kieffer F. Comparison of cutaneous bioavailability of cosmetic preparations containing caffeine or alpha-tocopherol applied on human skin models or human skin ex vivo at finite doses. Skin Pharmacol. Appl. Skin Physiol. 15 Suppl. 1 (2002) 40-58
15. Schmook F.P., Meingassner J.G., and Billich A. Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int. J. Pharm. 215 (2001) 51-56
16. Takahashi K., Sakano H., Numata N., Kuroda S., and Mizuno N. Effect of fatty acid diesters on permeation of anti-inflammatory drugs through rat skin. Drug Dev. Ind. Pharm. 28 (2002) 1285-1294
17. Bock U., Krause W., Otto J., and Haltner E. [Comparative in vitro and in vivo studies on the permeation and penetration of ketoprofen and ibuprofen in human skin]. Arzneimittelforschung 54 (2004) 522-529
18. Fan Q., Sirkar K.K., Wang Y., and Michniak B. In vitro delivery of doxycycline hydrochloride based on a porous membrane-based aqueous-organic partitioning system. J. Control. Release 98 (2004) 355-365
19. Santoyo S., Arellano A., Ygartua P., and Martin C. In vitro percutaneous absorption of piroxicam through synthetic membranes and abdominal rat skin. Pharm. Acta Helv. 71 (1996) 141-146
20. Artik S., and Ruzicka T. Complementary therapy for atopic eczema and other allergic skin diseases. Dermatol. Ther. 16 (2003) 150-163
21. Roeder A., Schaller M., Schäfer-Korting M., and Korting H.C. Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol. Physiol. 18 (2005) 3-11
22. Schäfer-Korting M., Kleuser B., Ahmed M., Höltje H.D., and Korting H.C. Glucocorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacol. Physiol. 18 (2005) 103-114
23. Schackert C., Korting H.C., and Schäfer-Korting M. Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo: characterisation of drugs with an increased benefit-risk ratio. BioDrugs 13 (2000) 267-277
24. Tanaka M., Iwata Y., Kouzuki Y., Taniguchi K., Matsuda H., Arima H., and Tsuchiya S. Effect of 2-hydroxypropyl-beta-cyclodextrin on percutaneous absorption of methyl paraben. J. Pharm. Pharmacol. 47 (1995) 897-900
25. Arima H., Miyaji T., Irie T., Hirayama F., and Uekama K. Enhancing effect of hydroxypropyl-beta-cyclodextrin on cutaneous penetration and activation of ethyl 4-biphenylyl acetate in hairless mouse skin. Eur. J. Pharm. Sci. 6 (1998) 53-59
26. Haberland A., Santos Maia C., Jores K., Dürrfeld M., Mehnert W., Schimke I., Christ B., and Schäfer-Korting M. Albumin effects on drug absorption and metabolism in reconstructed epidermis and excised pig skin. Altex 20 (2003) 3-9
27. Haberland A., Schreiber S., Maia C.S., Rübbelke M.K., Schaller M., Korting H.C., Kleuser B., Schimke I., and Schäfer-Korting M. The impact of skin viability on drug metabolism and permeation - BSA toxicity on primary keratinocytes. Toxicol. In Vitro 20 (2006) 347-354
28. I. Brinkmann, C.C. Müller-Goymann, Prednicarbate permeation through artificial skin construct from different formulations and their dilution, International Meeting on Pharmaceutics and Pharmaceutical Technology, Nuremberg, Germany, 2004.
29. Gysler A., Lange K., Korting H.C., and Schäfer-Korting M. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm. Res. 14 (1997) 793-797
30. Rohdewald P.J. Comparison of clinical efficacy of inhaled glucocorticoids. Arzneimittelforschung 48 (1998) 789-796
31. Lange K., Kleuser B., Gysler A., Bader M., Maia C., Scheidereit C., Korting H.C., and Schäfer-Korting M. Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids. Skin Pharmacol. Appl. Skin Physiol. 13 (2000) 93-103
32. Arellano A., Santoyo S., Martn C., and Ygartua P. Surfactant effects on the in vitro percutaneous absorption of diclofenac sodium. Eur. J. Drug. Metab. Pharmacokinet. 23 (1998) 307-312
33. Varshosaz J., Pardakhty A., and Baharanchi S.M. Sorbitan monopalmitate-based proniosomes for transdermal delivery of chlorpheniramine maleate. Drug Deliv. 12 (2005) 75-82
34. Cotovio J., Grandidier M.H., Portes P., Roguet R., and Rubinstenn G. The in vitro skin irritation of chemicals: optimisation of the EPISKIN prediction model within the framework of the ECVAM validation process. Altern. Lab. Anim. 33 (2005) 329-349
35. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
36. Lange K., Gysler A., Bader M., Kleuser B., Korting H.C., and Schäfer-Korting M. Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro. Pharm. Res. 14 (1997) 1744-1749
37. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci. 50 (1961) 874-875
38. Skoug J.W., Borin M.T., Fleishaker J.C., and Cooper A.M. In vitro and in vivo evaluation of whole and half tablets of sustained-release adinazolam mesylate. Pharm. Res. 8 (1991) 1482-1488
39. Nabi Z., Tavakkol A., Dobke M., and Polefka T.G. Bioconversion of vitamin E acetate in human skin. Curr. Probl. Dermatol. 29 (2001) 175-186
40. Hammell D.C., Stolarczyk E.I., Klausner M., Hamad M.O., Crooks P.A., and Stinchcomb A.L. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent. J. Pharm. Sci. 94 (2005) 828-836
41. Wassermann K., and Müller-Goymann C.C. Standardized cultivation of artificial skin constructs for drug permeation studies. Arch. Pharm. Pharm. Med. Chem. 333 (2000) 34 abstract
42. Boxman I.L., Kempenaar J., de Haas E., and Ponec M. Induction of HSP27 nuclear immunoreactivity during stress is modulated by vitamin C. Exp. Dermatol. 11 (2002) 509-517
43. Loth H. Vehicular influence on transdermal drug penetration. Int. J. Pharm. 68 (1991) 1-10
44. Dharmagunawardena B., and Charles-Holmes R. Contact dermatitis due to octyldodecanol in clotrimazole cream. Contact Dermatitis 36 (1997) 231
45. Tucker W.F. Contact dermatitis to Eutanol G. Contact Dermatitis 9 (1983) 88-89
46. Ponec M., Boelsma E., Gibbs S., and Mommaas M. Characterization of reconstructed skin models. Skin Pharmacol. Appl. Skin Physiol. 15 Suppl. 1 (2002) 4-17
47. Ponec M. Skin constructs for replacement of skin tissues for in vitro testing. Adv. Drug Deliv. Rev. 54 Suppl. 1 (2002) S19-S30
48. M. Schäfer-Korting, S. Schreiber, Use of skin equivalents for dermal absorption and toxicity. in: M. Dekker, M.S. Roberts, K.A. Walters, (Eds.), Dermal Absorption and Toxicity Assessment, 2nd Edition, in press.
49. Kalbitz J., Neubert R., and Wohlrab W. Modulation of drug penetration in the skin. Pharmazie 51 (1996) 619-637
50. Williams A.C., and Barry B.W. Penetration enhancers. Adv. Drug Deliv. Rev. 56 (2004) 603-618
51. Chien Y.W., Xu H.L., Chiang C.C., and Huang Y.C. Transdermal controlled administration of indomethacin. I. Enhancement of skin permeability. Pharm Res. 5 (1988) 103-106
52. Ng K.M., Chu I., Bronaugh R.L., Franklin C.A., and Somers D.A. Percutaneous absorption and metabolism of pyrene, benzo[a]pyrene, and di(2-ethylhexyl) phthalate: comparison of in vitro and in vivo results in the hairless guinea pig. Toxicol. Appl. Pharmacol. 115 (1992) 216-223
53. Qiao G.L., and Riviere J.E. Systemic uptake and cutaneous disposition of pentachlorophenol in a sequential exposure scenario: effects of skin preexposure to benzo[a]pyrene. J. Toxicol. Environ. Health A 65 (2002) 1307-1331